InMed Pharmaceuticals Inc. (INM) Fair Value 2026

INM · Drug Manufacturers - Specialty & Generic ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

5.2 /10

32 fundamental signals · 0 models active

Value Trap Risk

WARN (46/100)

Quick Summary — As of 2026-08-28, InMed Pharmaceuticals Inc. (INM) trades at $1.38. QOC: 5.2/10. Value Trap Risk: 46/100 (WARN). 0/13 models active.

Key Facts

Ticker
INM
Price
$1.38
Quality Score
5.2/10
Value Trap Risk
46/100
Models Active
0/13
Last Updated
Strength: 0 independent models provide multi-angle coverage
Risk: Value Trap score of 46 suggests caution despite apparent undervaluation

What Fair Value Does Each Model Give INM?

0 Intrinsic Value Models vs. Current Price ($1.38)

Core Models (Unlocked)
Model Fair Value Upside

All Models Active

All 0 models are displayed above.

What Is InMed Pharmaceuticals Inc. (INM) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, InMed Pharmaceuticals Inc. currently lacks sufficient data across our 13-model framework. As more financial data is processed from SEC filings, our models will generate intrinsic value estimates.

What Do the Models Say About INM?

0 of 13 models are currently active for INM. See which stocks rank higher →

How Does INM Rank in Drug Manufacturers - Specialty & Generic?

Among 112 Drug Manufacturers - Specialty & Generic stocks, INM ranks #73 by Quality of Company score. CirclFi's QOC score of 5.2/10 evaluates 32 fundamental signals. A score of 5.2 reflects mixed fundamentals.

See all Most Undervalued Drug Manufacturers - Specialty & Generic Stocks →

The Drug Manufacturers - Specialty & Generic sector introduces analytical considerations specific to pharmaceutical industry businesses. For InMed Pharmaceuticals Inc., metrics like biosimilar competition timeline provide important context that general-purpose valuation models may underweight.

Is INM a Value Trap?

CirclFi's Value Trap algorithm assigns INM a score of 46/100 (WARN). This is a warning signal. Additional research into recent 10-Q filings is recommended. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

0 of 13 models are active for InMed Pharmaceuticals Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, InMed Pharmaceuticals Inc. earns a quality score of 5.2/10. This mixed rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency. Our Value Trap detector shows moderate caution signals worth monitoring.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every INM valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy InMed Pharmaceuticals Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Drug Manufacturers - Specialty & Generic Stocks Should You Also Analyze?

11 related Drug Manufacturers - Specialty & Generic stocks with 13-model coverage

CGCCanopy Growth CorporationQOC 5.3SKYISky Century Investment, Inc.QOC 5.2YCBDcbdMD, Inc.QOC 5.3IMCCIM Cannabis Corp.QOC 5.2CVSICV Sciences, Inc.QOC 5.4AMLXAmylyx Pharmaceuticals, Inc.QOC 5.1KAYSKaya Holdings, Inc.QOC 3.9AMRXAmneal Pharmaceuticals, Inc.QOC 8.3ZYBTZhengye Biotechnology Holding LimitedQOC 6.2UTHRUnited Therapeutics CorporationQOC 9.6AMPHAmphastar Pharmaceuticals, Inc.QOC 9.4

Read investment analysis: CGC · SKYI · YCBD · IMCC · CVSI · AMLX · KAYS · AMRX · ZYBT · UTHR · AMPH

Which Other Stocks Have a Similar Quality Score to INM?

7 companies across all industries closest to INM’s Quality of Company score of 5.2/10.

FRBPFRANKLIN BSP CAP CORPQOC 5.2STNEStoneCo Ltd.QOC 5.2FGLFounder Group LimitedQOC 5.2VIPVulcan Infrastructure and Power Inc.QOC 5.2EXODExodus Movement, Inc.QOC 5.2DNUTKrispy Kreme, Inc.QOC 5.2NVDANVIDIA CorporationQOC 10.0

Read investment analysis: FRBP · STNE · FGL · VIP · EXOD · DNUT · NVDA

Where Does INM Sit in CirclFi's Drug Manufacturers - Specialty & Generic Rankings?

INM is ranked against every other Drug Manufacturers - Specialty & Generic stock CirclFi covers in each of these screens.

See all Drug Manufacturers - Specialty & Generic stocks ranked →

What Else Do Investors Ask About InMed Pharmaceuticals Inc.’s Valuation?

What is InMed Pharmaceuticals Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for InMed Pharmaceuticals Inc. (INM). The Quality of Company score is 5.2/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is INM overvalued or undervalued right now?

At $1.38, 0 of 0 active models suggest INM may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits InMed Pharmaceuticals Inc.'s business model in Drug Manufacturers - Specialty & Generic.

What does a Quality of Company score of 5.2 mean for INM?

InMed Pharmaceuticals Inc.'s QOC of 5.2/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on INM?

CirclFi analyzes INM with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 0 of 13 are active for this stock. Read the full methodology →

Is INM a value trap in 2026?

InMed Pharmaceuticals Inc.'s Value Trap score is 46/100 (WARN). This elevated score suggests the stock may look undervalued but faces deteriorating fundamentals — declining margins, rising debt, or shrinking revenue could make the apparent discount deceptive. Browse our ranked stock lists to compare value-trap scores across industries. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns InMed Pharmaceuticals Inc. (INM) a Quality of Company score of 5.2/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/INM/ · Methodology
Primary sources for this INM valuation
  • Financial statements: InMed Pharmaceuticals Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001728328) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for INM as of ; valuations recomputed .